AstraZeneca Pharma India Limited has submitted a mandatory compliance certificate to the stock exchanges on February 19, 2026. The certificate, dated February 5, 2026, was issued by the Registrar and Transfer Agent (RTA), Integrated Registry Management Services Private Limited. It confirms the company’s adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, regarding the dematerialization of securities for the period starting January 1, 2026, to January 31, 2026.
Regulatory Compliance Filing with Stock Exchanges
AstraZeneca Pharma India Limited officially communicated to the stock exchanges, including BSE Limited and the National Stock Exchange of India Ltd., the submission of a crucial regulatory document. The submission was made on February 19, 2026.
Confirmation of Securities Dematerialization
The core of the announcement is the enclosure of a certificate confirming compliance with Regulation 74(5) of the relevant SEBI Depositories and Participants Regulations, 2018. This confirmation was provided by the company’s Registrar and Transfer Agent (RTA), Integrated Registry Management Services Private Limited, in a certificate dated February 5, 2026.
Specifically, the RTA confirmed that for the period covering January 1, 2026, to January 31, 2026, the company has duly performed the necessary actions within 15 days of receiving security certificates for dematerialization:
- The securities specified in the certificates, which were dematerialized, remain listed on the respective stock exchanges.
- Any physical certificates forwarded by participants were mutilated and canceled.
- The name of the depository has been substituted as the registered owner in the company’s records.
The document was authorized and digitally signed by Bhavana Agrawal, Chief Financial Officer & Director of AstraZeneca Pharma India Limited.
Source: BSE
